عرض مصدر بي دي-128907

{{معلومات دواء
| Verifiedfields = changed
| verifiedrevid = 451226356
| IUPAC_name = (4aR,10bR)-3,4a,4,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol
| image = PD-128907_structure.png
| width = 200

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL         / P       / POM / CD -->
| legal_US = <!-- OTC                   / Rx-only  -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 123594-64-9
| CAS_supplemental = <br />300576-59-4 (hydrochloride)
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 5311346
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 94015
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 23180492

<!--Chemical data-->
| C=14 | H=19 | N=1 | O=3 
| molecular_weight = 249.305 g/mol
| smiles = c23cc(O)ccc3OCC1C2OCCN1CCC
| InChI             = 1/C14H19NO3/c1-2-5-15-9-17-7-12-11-6-10(16)3-4-14(11)18-8-13(12)15/h3-4,6,12-13,16H,2,5,7-9H2,1H3/t12-,13-/m1/s1
| InChIKey          = ZFSOBPVEIKTNQS-CHWSQXEVBE
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C14H19NO3/c1-2-5-15-9-17-7-12-11-6-10(16)3-4-14(11)18-8-13(12)15/h3-4,6,12-13,16H,2,5,7-9H2,1H3/t12-,13-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = ZFSOBPVEIKTNQS-CHWSQXEVSA-N
}}
'''بي دي-128,907''' {{إنج|PD-128,907}} هي مادة كيميائية ذات تأثير دوائي درست خواصها، فهي [[ناهض (علم الأدوية)|ناهضة]] ل[[مستقبلات الدوبامين]] قوية وانتقائية ل[[مستقبل الدوبامين د2]] و[[مستقبل الدوبامين د3]].<ref>DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, Pugsley TA, Wise LD. Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers. ''Journal of Medicinal Chemistry''. 1990 Jan;33(1):445-50. {{PMID|1967318}}</ref> استخدمت هذه المادة لدراسة دور هذين المستقبلين في [[دماغ|الدماغ]]، مثل تأثير [[المستقبل الذاتي]] المثبط لتحديد للمزيد من تحرير الدوبامين<ref>Koeltzow TE, Xu M, Cooper DC, Hu XT, Tonegawa S, Wolf ME, White FJ. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. ''Journal of Neuroscience''. 1998 Mar 15;18(6):2231-8. {{PMID|9482807}}</ref> بالإضافة [[ناقل عصبي|للنواقل العصبية]] الأخرى.<ref>Chen G, Kittler JT, Moss SJ, Yan Z. Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. ''Journal of Neuroscience''. 2006 Mar 1;26(9):2513-21. {{PMID|16510729}}</ref>

في الدراسات الحيوانية ظهر أنه يقلل من تسمم فرط جرعة ال[[كوكايين]].<ref>Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, Shannon HE, Gasior M. Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]. ''Journal of Pharmacology and Experimental Therapeutics''. 2004 Mar;308(3):957-64. {{PMID|14711932}}</ref><ref>Witkin JM, Levant B, Zapata A, Kaminski R, Gasior M. The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors. ''Journal of Pharmacology and Experimental Therapeutics''. 2008 Sep;326(3):930-8. {{PMID|18566292}}</ref>